Security key
04965N104
Atrium Therapeutics, Inc. - COMMON STOCK (RNA)
CUSIP: 04965N104
Q1 2026 13F Holders as of 31 Mar 2026
- Security type / class
- Equity / COMMON STOCK
- Total 13F shares
- 14,832,543
- Total 13F value
- $198,321,325
- Share change
- +13,174,314
- Put/Call ratio
- 1729%
- SEC-reported price per share
- $13.37
- Number of holders
- 160
- Value change
- +$176,150,803
- Number of buys
- 154
- Shares outstanding
- 17,127,721
Holder snapshot
6 signals
Security identity
Names, identifiers, and filing context for this profile.
1 source field
Report period
Q1 2026
Institutions
160
Top holders
10
RNA full security history
Ownership snapshot
Full 13F holder table
Atrium Therapeutics, Inc. SEC filings
Atrium Therapeutics, Inc. company facts
Broader feeds
Ownership snapshot
Top reported holders of RNA - Atrium Therapeutics, Inc. - COMMON STOCK (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
Troy E. Wilson
Disclosed value leader
—
Comparable rows
0/3
Latest evidence
27 Feb 2026
3/4/5
Some rows are evidence-backed but not safely comparable across classes.
3 rows are not safely comparable across share classes.
Quick read
SEC ownership evidence is available, but the rows are not safely comparable across share classes.
0 of 3 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens Troy E. Wilson's linked filing trail.
Detailed SEC evidence table Showing 1-3 of 3 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| Troy E. Wilson |
3/4/5
Director
|
—
mixed-class rows
|
—
31,731 shares
mixed-class rows
|
— | 27 Feb 2026 |
| Carsten Boess |
3/4/5
Director
|
—
mixed-class rows
|
—
31,005 shares
mixed-class rows
|
— | 27 Feb 2026 |
| Simona Skerjanec |
3/4/5
Director
|
—
mixed-class rows
|
—
25,902 shares
mixed-class rows
|
— | 27 Feb 2026 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
13F holder rows
Institutional holders as of Q1 2026
Investor-level positions for this CUSIP, loaded as an interactive table.
Institutions
160
Shares
14,832,543
Rows available
160
| Investor | Option | Weight % | Change % | SEC-reported value | * Price | Shares | Share Change | Activity | Report Period |
|---|
* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.
Compare Q1 2026 vs Q1 2026 Across Filers
Q1 2026 holders
160
Q1 2026 holders
160
Holder diff
0
| Investor | Q1 2026 Shares | Q1 2026 Shares | Share Diff | Share Chg % | Q1 2026 value | Q1 2026 value | Value change | Value Chg % |
|---|